Logotype for Pila Pharma

Pila Pharma (PILA) investor relations material

Pila Pharma Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Pila Pharma
Q2 2025 earnings summary27 Aug, 2025

Executive summary

  • Strategic focus shifted to obesity, alongside type 2 diabetes, driven by industry and investor interest in differentiated metabolic treatments and oral TRPV1 antagonist approaches.

  • Rights issue and associated financings raised nearly SEK 30 million before costs, oversubscribed by 293.5%, with strong shareholder and management participation.

  • Engagements with pharmaceutical companies highlighted the need for more data, prompting a focus on proof-of-concept studies in obesity.

  • Founders and board members increased their stakes, now holding about 15% of shares collectively, with significant set-offs for executive remuneration.

  • Clinical trial application for PP-CT03 in obesity and diabetes advanced.

Financial highlights

  • Operating income for H1 2025 was TSEK 851, up from TSEK 683 year-over-year.

  • EBIT for H1 2025 was TSEK -4,092, nearly unchanged from TSEK -4,082 in H1 2024.

  • Burn rate remained consistent with the previous half-year period.

  • Cash position improved significantly post-period due to the oversubscribed rights issue.

  • Equity at period end was TSEK 1,159, down from TSEK 2,575 year-over-year.

Outlook and guidance

  • Preclinical in vivo rat studies for obesity are set to begin in autumn, with results expected around New Year or before the TO2 warrant exercise period in February 2026.

  • Pending positive preclinical results and continued funding, human clinical trials in obesity are planned.

  • Funds raised are sufficient to finance rat obesity studies and clinical trial application preparations for both diabetes and obesity.

  • Additional funding possible from warrant exercise, potentially up to SEK 90 million.

  • The company is well-funded for upcoming studies, with prudent spending expected.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Pila Pharma earnings date

Logotype for Pila Pharma
Q4 202526 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Pila Pharma earnings date

Logotype for Pila Pharma
Q4 202526 Feb, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage